Literature DB >> 2832472

Vascular angiotensin converting enzyme activity in spontaneously hypertensive rats and its inhibition with cilazapril.

Y Nakamura1, K Nakamura, T Matsukura, K Nakamura.   

Abstract

Angiotensin converting enzyme (ACE) activity was examined in large arteries and veins of rats and found to be present in most of the arteries and to a lesser extent in the veins, except for the femoral vessels which showed higher ACE activity in the vein than in the artery. For the aorta and all its branches, ACE activity was higher in the aorta and its branches in spontaneously hypertensive rats (SHR) than in age-matched normotensive Wistar-Kyoto rats (WKY), with the exception of the hepatic, pulmonary and basilar arteries where the levels were similar for SHR and WKY. For the vena cava and brachial vein, ACE activity was also higher in SHR than WKY but for most other veins the activity was the same with the exception of the pulmonary vein where ACE activity was higher in WKY. The acute treatment of SHR with cilazapril, an ACE inhibitor (0.3 and 3 mg/kg orally, for 4h) decreased aortic blood pressure and ACE activity in arterial and venous mesenteric and renal vessels in a dose-dependent fashion. Cilazapril, at the threshold hypotensive dose, markedly decreased ACE activity in each pair of aortic segments, carotid, pulmonary, subclavian, brachial and femoral vessels to a degree which was equivalent to that caused by the high dose. The effect outlasted a fall in blood pressure 24 h later. This was associated with a marked decrease in plasma angiotensin II and III and accumulation of angiotensin 1 at 4 h. No increase in plasma bradykinin or kallidin levels was detected.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2832472

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  9 in total

1.  Effects of acute and chronic cilazapril treatment in spontaneously hypertensive rats.

Authors:  W Fischli; F Hefti; J P Clozel
Journal:  Br J Clin Pharmacol       Date:  1989       Impact factor: 4.335

Review 2.  Cilazapril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in cardiovascular disease.

Authors:  F Deget; R N Brogden
Journal:  Drugs       Date:  1991-05       Impact factor: 9.546

3.  Vascular protection with cilazapril.

Authors:  J P Clozel; J S Powell; H Kuhn; R K Müller; F Hefti; H R Baumgartner
Journal:  Drugs       Date:  1991       Impact factor: 9.546

Review 4.  The mechanisms of coronary restenosis: insights from experimental models.

Authors:  G A Ferns; T Y Avades
Journal:  Int J Exp Pathol       Date:  2000-04       Impact factor: 1.925

5.  Comparisons in vitro, ex vivo, and in vivo of the actions of seven structurally diverse inhibitors of angiotensin converting enzyme (ACE).

Authors:  D W Cushman; F L Wang; W C Fung; G J Grover; C M Harvey; R J Scalese; S L Mitch; J M DeForrest
Journal:  Br J Clin Pharmacol       Date:  1989       Impact factor: 4.335

Review 6.  ACE-inhibitors and atherosclerosis.

Authors:  E Ambrosioni; S Bacchelli; D Degli Esposti; C Borghi
Journal:  Eur J Epidemiol       Date:  1992-05       Impact factor: 8.082

7.  Alcohol withdrawal at home. Pilot project for frail elderly people.

Authors:  D J Evans; S D Street; D J Lynch
Journal:  Can Fam Physician       Date:  1996-05       Impact factor: 3.275

8.  Prevention of intimal thickening after endothelial removal by a nonpeptide angiotensin II receptor antagonist, losartan.

Authors:  H Azuma; Y Niimi; H Hamasaki
Journal:  Br J Pharmacol       Date:  1992-07       Impact factor: 8.739

9.  Antihypertensive Effects of Polyphenolic Extract from Korean Red Pine (Pinus densiflora Sieb. et Zucc.) Bark in Spontaneously Hypertensive Rats.

Authors:  Kwan Joong Kim; Eun-Sang Hwang; Min-Jeong Kim; Ji-Ho Park; Dae-Ok Kim
Journal:  Antioxidants (Basel)       Date:  2020-04-19
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.